Publicly traded biopharmaceutical firms can have large, sometimes triple-bagger, expectations placed on them by Wall Street analysts. This is especially true for companies like Trevi Therapeutics NASDAQ: TRVI, which don’t yet have any products approved by the Food and Drug Administration (FDA). This means these firms may have little or no revenue, as is the case for Trevi.Trevi Therapeutics TodayTRVITrevi Therapeutics$3.10 +0.15 (+5.08$0.97▼$4.00Price Target$7.80Add to WatchlistA lot of proj ...